Lajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.
Lajos Pusztai, MD, PhD
Advertisement
Articles by Lajos Pusztai, MD, PhD
Lajos Pusztai, MD, DPhil, discusses recent data from the phase 3 KEYNOTE-522 trial of patients with triple-negative breast cancer.
Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Advertisement
Latest Updated Articles
Dr. Pusztai Discusses DNA Abnormalities in Breast CancerPublished: September 9th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
